Clinical trials: Vitiligo
NonSegmental Vitiligo
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
- Trial name
- NCT06113471
- Testing
- Povorcitinib
- Where
- 86 sites in United States, Bulgaria and 7 more
- Volunteers
- 450 people
- Sponsor
- Incyte Corporation
Vitiligo
Investigating Healthcare Disparities in Vitiligo
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are…
- Trial name
- NCT06097494
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 39,374 people
- Sponsor
- Momentum Data
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Vitiligo
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
Prospective randomized within-subject controlled feasibility study to evaluate the clinical performance of RECELL for repigmentation of stable, depigmented lesions.
- Trial name
- NCT04271501
- Testing
- Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB), RECELL 1:5 and Ultraviolet Lamp (UVB), RECELL 1:10 and Ultraviolet Lamp (UVB)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avita Medical
Vitiligo, Melanoma (Skin)
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.
- Conditions
- Vitiligo, Melanoma (Skin), Nonmelanoma Skin Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04969419
- Testing
- Exposure of skin cancer of interest
- Where
- United Kingdom
- Volunteers
- 75,771 people
- Sponsor
- Momentum Data
NonSegmental Vitiligo
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
- Trial name
- NCT06113445
- Testing
- Povorcitinib
- Where
- 100 sites in United States, Belgium and 8 more
- Volunteers
- 467 people
- Sponsor
- Incyte Corporation
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Vitiligo, Depressive Episode
Mental Health Associations With Vitiligo
This cohort study is a large population-based study in the UK to determine the risks of comorbid mental health conditions (including depression, anxiety and other potential psychological complications of vitiligo) in adults with…
- Conditions
- Vitiligo, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04953338
- Testing
- Exposure of mental health condtion of interest
- Where
- United Kingdom
- Volunteers
- 36,104 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Non-Segmental Vitiligo
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- NCT04927975
- Testing
- Upadacitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 185 people
- Sponsor
- AbbVie
Vitiligo
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
- Trial name
- NCT06625177
- Testing
- TEV-53408
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Nonsegmental Vitiligo With Genital Involvement
A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo
An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks.
- Trial name
- NCT05750823
- Testing
- Ruxolitinib Cream
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- Incyte Corporation
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo.
- Trial name
- Tranquillo 2 (NCT06072183)
- Testing
- Ritlecitinib
- Where
- 229 sites in United States, Australia and 16 more
- Volunteers
- 1,571 people
- Sponsor
- Pfizer
Vitiligo
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
- Trial name
- NCT06109649
- Testing
- Afamelanotide and NB-UVB Light, NB-UVB Light
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 200 people
- Sponsor
- Clinuvel, Inc.
NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable…
- Trial name
- MTII-VIT (NCT07437560)
- Testing
- Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hudson Biotech
Non-Segmental Vitiligo
A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.
- Trial name
- NCT07667569
- Testing
- ACT-777991
- Volunteers
- 30 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Nonsegmental Vitiligo
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin…
- Trial name
- NCT07108283
- Testing
- Zasocitinib
- Where
- 69 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Takeda
Vitiligo, Pediatric ALL
Efficacy and Safety of 308-nm Excimer Lamp Combined With Tacrolimus vs Tacrolimus as Monotherapy in Treating Vitiligo on Children
Vitiligo is a auto immune that impact 2% of the global population, regardless from the phototype. Even though it affects patients in a physical way through loss of pigmentation, it is also impacting them on a mental/emotional…
- Conditions
- Vitiligo, Pediatric ALL, Dermatologic Disease, Autoimmune Diseases
- Trial name
- NCT06035614
- Testing
- exciplex, Tacrolimus ointment
- Where
- Jordan
- Volunteers
- 50 people
- Sponsor
- Clarteis
Vitiligo
Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.
Vitiligo is an autoimmune depigmentation disorder affecting 0.5 to 1% of the population worldwide. Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in…
- Trial name
- NCT06446063
- Testing
- Test product, Control Product
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Non-segmental Vitiligo
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study
- Trial name
- NCT07172347
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD